Advertisement

18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer

  • Akira Toriihara
  • Heying Duan
  • Holly M. Thompson
  • Sonya Park
  • Negin Hatami
  • Lucia Baratto
  • Alice C. FanEmail author
  • Andrei IagaruEmail author
Short Communication
  • 287 Downloads

Abstract

Purpose

The usefulness of positron emission tomography/computed tomography (PET/CT) using (18F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid peptide [PEG3-E{c(RGDyk)}2] (18F-FPPRGD2) in patients with metastatic renal cell cancer (mRCC) has not been evaluated; therefore, we were prompted to conduct this pilot study.

Methods

Seven patients with mRCC were enrolled in this prospective study. 18F-FPPRGD2 and 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) PET/CT images were evaluated in a per-lesion analysis. Maximum standardized uptake value (SUVmax) and tumor-to-background ratio (T/B) were measured for all detected lesions, both before and after starting antiangiogenic therapy.

Results

Sixty lesions in total were detected in this cohort. SUVmax from 18F-FPPRGD2 PET/CT was lower than that from 18F-FDG PET/CT (4.4 ± 2.9 vs 7.8 ± 5.6, P < 0.001). Both SUVmax and T/B from 18F-FPPRGD2 PET/CT decreased after starting antiangiogenic therapy (SUVmax, 4.2 ± 3.2 vs 2.6 ± 1.4, P = 0.003; T/B, 3.7 ± 3.2 vs 1.5 ± 0.8, P < 0.001). Average changes in SUVmax and T/B were − 29.3 ± 23.6% and − 48.1 ± 28.3%, respectively.

Conclusions

18F-FPPRGD2 PET/CT may be an useful tool for monitoring early response to antiangiogenic therapy in patients with mRCC. These preliminary results need to be confirmed in larger cohorts.

Keywords

Renal cell cancer 18F-FPPRGD2 18F-FDG PET/CT Antiangiogenic therapy 

Notes

Funding

The study was supported by a grant to Dr. Holly M. Thompson from Alpern Foundation. Alice C. Fan receives funding support from ASCO Conquer Cancer Foundation Career Development Award and is a founder of Molecular Decisions Inc. Andrei Iagaru receives institutional research support from GE Healthcare.

Compliance with ethical standards

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Conflict of interest

Alice C. Fan receives funding support from ASCO Conquer Cancer Foundation Career Development Award and is a founder of Molecular Decisions Inc.

Andrei Iagaru receives institutional research support from GE Healthcare (unrelated to this study).

Supplementary material

259_2019_4295_MOESM1_ESM.pdf (124 kb)
ESM 1 (PDF 123 kb)

References

  1. 1.
    Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:804–34.CrossRefGoogle Scholar
  2. 2.
    Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, et al. Glioblastoma multiforme recurrence: an exploratory study of 18F FPPRGD2 PET/CT. Radiology. 2015;277:497–506.CrossRefGoogle Scholar
  3. 3.
    Minamimoto R, Karam A, Jamali M, Barkhodari A, Gambhir SS, Dorigo O, et al. Pilot prospective evaluation of 18F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer. Eur J Nucl Med Mol Imaging. 2016;43:1047–55.CrossRefGoogle Scholar
  4. 4.
    Iagaru A, Mosci C, Shen B, Chin FT, Mittra E, Telli ML, et al. 18F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. Radiology. 2014;273:549–59.CrossRefGoogle Scholar
  5. 5.
    Withofs N, Signolle N, Somja J, Lovinfosse P, Nzaramba EM, Mievis F, et al. 18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology. J Nucl Med. 2015;56:361–4.CrossRefGoogle Scholar
  6. 6.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefGoogle Scholar
  7. 7.
    Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, et al. Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49:22–9.CrossRefGoogle Scholar
  8. 8.
    Yoon HJ, Kang KW, Chun IK, Cho N, Im SA, Jeong S, et al. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2014;41:1534–43.CrossRefGoogle Scholar
  9. 9.
    Withofs N, Martinive P, Vanderick J, Bletard N, Scagnol I, Mievis F, et al. [18F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:654–62.CrossRefGoogle Scholar
  10. 10.
    Shenoy N, Pagliaro L. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. Ann Oncol. 2016;27:1685–95.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Nuclear Medicine and Molecular Imaging, Department of RadiologyStanford UniversityStanfordUSA
  2. 2.Department of Nuclear MedicineKaiser PermanenteSanta ClaraUSA
  3. 3.Division of Oncology, Department of MedicineStanford UniversityStanfordUSA

Personalised recommendations